Inhalation-type pharmaceutical composition for the treatment of Alzheimer&#39;s disease and preparation method thereof

ABSTRACT

The present invention provides an inhalation-type pharmaceutical composition for Alzheimer&#39;s disease and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising rivastigmine hydrogen tartrate, donepezil hydrochloride, galantamine hydrobromide, memantine hydrochloride, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can provide the convenience of taking medicine and removing harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

PRIORITY CLAIM

This application claims the benefit of the filing date of Taiwan PatentApplication No. 103110986, filed Mar. 25, 2014, entitled“INHALATION-TYPE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OFALZHEIMER'S DISEASE AND PREPARATION METHOD THEREOF,” and the contents ofwhich are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

The present invention relates to an inhalation-type pharmaceuticalcomposition and the preparation method thereof, more particularly, tothe inhalation-type pharmaceutical composition used for the treatment ofAlzheimer's disease and the preparation method thereof.

BACKGROUND

The main clinical feature of Alzheimer's disease (AD) is a cognitivedecline that leads to progressive memory loss and impairment in languageand emotion. Therefore, the patient care and the treatment of theAlzheimer's disease are expensive and degraded quality of life forpatient's families.

Therefore, the treatment of Alzheimer's disease has become a veryimportant topic. Nowadays, the U.S. Food and Drug Administration (FDA)has approved two types of medications for the management of Alzheimer'sdisease: N-methyl-D-aspartate receptor antagonist including memantinehydrochloride and cholinesterase inhibitors including rivastigminehydrogen tartrate, donepezil hydrochloride, and galantaminehydrobromide. Those aforementioned approved pharmaceuticals can inhibitcholinesterase, repress the hydrolysis of neurotransmitteracetylcholine, and increase the acetylcholine content in human brain,which in turn may improve symptoms and defer the process of memory-loss.However, those pharmaceutical treatments are unable to cure Alzheimer'sdisease, but only relieve certain AD symptoms. Furthermore, thosemedications will bring some side effects to AD patients, includingnausea, headache, diarrhea, insomnia, pain, hallucination, or dizziness,etc.

Therefore, the current treatment for Alzheimer's disease lacks amedicine combined with the curative effect for Alzheimer's disease andwithout side effects to patients.

SUMMARY OF THE INVENTION

Therefore, the present invention provides an inhalation-typepharmaceutical composition for the treatment of Alzheimer's disease,which comprises a first gas and an atomized medicine. The first gascomprises hydrogen, where the gas volume concentration of the hydrogenin the inhalation-type pharmaceutical composition is between 2 to 96%.The atomized medicine is selected from a group comprising rivastigminehydrogen tartrate, donepezil hydrochloride, galantamine hydrobromide,memantine hydrochloride, and any combination thereof.

According to the preparation method for the inhalation-typepharmaceutical composition for the treatment of Alzheimer's diseaseprovided by one embodiment of the present invention, the first gas is agas mixture of hydrogen and oxygen generated from electrolyzing water,where the volume ratio of hydrogen to oxygen is 2:1. In the embodiment,the gas volume concentration of hydrogen in the inhalation-typepharmaceutical composition is between 2 to 66.66%. Furthermore, theinhalation-type pharmaceutical composition of the present inventionfurther comprises a second gas. The second gas is used to reduce the gasvolume concentration of hydrogen in the inhalation-type pharmaceuticalcomposition, wherein the second gas is a gas selected from a groupcomprising air, water vapor, inert gas, oxygen or any combinationthereof. In the present embodiment, the gas volume concentration ofhydrogen in the inhalation-type pharmaceutical composition can bebetween 4.7 to 66.66%, but is not limited to this range.

According to the inhalation-type pharmaceutical composition for thetreatment of Alzheimer's disease provided by another embodiment of thepresent invention, the gas volume concentration of hydrogen in theinhalation-type pharmaceutical composition is between 60 to 66.66%. Inaddition, the inhalation-type pharmaceutical composition for thetreatment of Alzheimer's disease provided by another embodiment of thepresent invention, the gas volume concentration of hydrogen in theinhalation-type pharmaceutical composition is larger than 66.66%.

Furthermore the invention further provides a preparation method for theinhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease, and comprises the following steps:

(S1) preparing a first gas, wherein the first gas comprises hydrogen;

(S2) atomizing a medicinal liquid in order to generate an atomizedmedicine, wherein the atomized medicine is selected from a groupcomprising rivastigmine hydrogen tartrate, donepezil hydrochloride,galantamine hydrobromide, memantine hydrochloride, and any combinationthereof; and

(S3) mixing the first gas and the atomized medicine in order to generatethe inhalation-type pharmaceutical composition, wherein the gas volumeconcentration of hydrogen in the inhalation-type pharmaceuticalcomposition is between 2 to 96%.

According to the preparation method for the inhalation-typepharmaceutical composition for the treatment of Alzheimer's diseaseprovided by one embodiment of the present invention, the first gas isgenerated by electrolyzing water in step (S1) of the present invention.The first gas comprises a gas mixture of hydrogen and oxygen, where thevolume ratio of hydrogen to oxygen is 2:1.

According to the preparation method for the inhalation-typepharmaceutical composition for the treatment of Alzheimer's diseaseprovided by another embodiment of the present invention, the method ofthe present invention further comprises the following steps:

(S21) preparing a first gas, wherein the first gas comprises hydrogen;

(S22) atomizing a medicinal liquid to generate an atomized medicine,wherein the atomized medicine is selected from a group comprisingrivastigmine hydrogen tartrate, donepezil hydrochloride, galantaminehydrobromide, memantine hydrochloride, and any combination thereof;

(S23) preparing a second gas; and

(S24) mixing the first gas, the second gas, and the atomized medicine inorder to generate the inhalation-type pharmaceutical composition. In theembodiment, the gas volume concentration of hydrogen in theinhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease can be reduced by adding the second gas.

Furthermore, according to the preparation method for the inhalation-typepharmaceutical composition for the treatment of Alzheimer's diseaseprovided by another embodiment of the present invention, the gas volumeconcentration of hydrogen in the inhalation-type pharmaceuticalcomposition is generally between 60%˜66.61%. And according to thepreparation method for the inhalation-type pharmaceutical compositionfor the treatment of Alzheimer's disease provided by another embodimentof the present invention, the gas volume concentration of hydrogen inthe inhalation-type pharmaceutical composition generally is larger than66.66%.

Compared to conventional technology, the present invention provides aninhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease and the preparation method thereof. Theinhalation-type pharmaceutical composition of the present invention canprovide the convenience of taking medicine and removing harmful radicalsin the body of the patient through the use of hydrogen while alsoincreases the absorption effect of the medicine for the patient by usingan atomized medicine. Therefore, the present invention can provide atreatment for Alzheimer's disease that combines the convenience oftaking the medicine while also having better curative effects on theuser.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a method flowchart illustrating a preparation method for aninhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease according to one embodiment of the presentinvention.

FIG. 2 is a method flowchart illustrating a preparation method for aninhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease according to another embodiment of the presentinvention.

FIG. 3 is a schematic diagram of an electrolysis device illustratingstep (S1) in the preparation method for an inhalation-typepharmaceutical composition for the treatment of Alzheimer's diseaseaccording to one embodiment of the present invention.

FIG. 4 is a schematic diagram of a gas mixing system illustrating step(S2) and (S3) in the preparation method of the inhalation-typepharmaceutical composition for the treatment of Alzheimer's diseaseaccording to one embodiment of the present invention.

DETAILED DESCRIPTION

In order to allow the advantages, spirit and features of the presentinvention to be more easily and clearly understood, the embodiments andappended drawings thereof are discussed in the following. However, thepresent invention is not limited to the embodiments and appendeddrawings.

The present invention provides an inhalation-type pharmaceuticalcomposition for the treatment of Alzheimer's disease, which comprises afirst gas and an atomized medicine. The first gas comprises hydrogen.The gas volume concentration of hydrogen in the inhalation-typepharmaceutical composition is between 2 to 96%. The atomized medicine isselected from a group comprising rivastigmine hydrogen tartrate,donepezil hydrochloride, galantamine hydrobromide, memantinehydrochloride, and any combination thereof.

In one embodiment of the present invention, the first gas furthercomprises an oxygen and is a gas mixture of hydrogen and oxygengenerated from electrolyzing water, where the volume ratio of hydrogento oxygen is 2:1. The atomized medicine is generated by atomizing orvaporizing a medicinal liquid, wherein the medicinal liquid is selectedfrom a group comprising rivastigmine hydrogen tartrate, donepezilhydrochloride, galantamine hydrobromide, memantine hydrochloride, andany combination thereof. The above medicine for the treatment ofAlzheimer's disease is well known to those skilled in the art, and hencewill not be described in further detail. In the present embodiment, thegas volume concentration of hydrogen in the inhalation-typepharmaceutical composition is between 2 to 66.66%.

The inhalation-type pharmaceutical composition of the present inventionfurther comprises a second gas. The second gas is used to reduce the gasvolume concentration of hydrogen in the inhalation-type pharmaceuticalcomposition, wherein the second gas is a gas selected from a groupcomprising air, water vapor, inert gas, oxygen or any combinationthereof. In the present embodiment, the gas volume concentration ofhydrogen in the inhalation-type pharmaceutical composition can bebetween 4.7 to 66.66%, but is not limited to this range.

In another embodiment of the present invention, the inhalation-typepharmaceutical composition is made by mixing the first gas and theatomized medicine generated by atomizing a 40 c.c. medicinal liquid,where the gas volume concentration of hydrogen in the inhalation-typepharmaceutical composition is between 60 to 66.66%. In anotherembodiment of the present invention, the required hydrogen can beprovided by using a hydrogen bottle. Then, the hydrogen provided by thehydrogen bottle is mixed with the atomized medicine, where at this timethe gas volume concentration of hydrogen in the inhalation-typepharmaceutical composition is larger than 66.66%, for example between 67to 96%. In another embodiment of the present invention, the hydrogen canalso be directly collected from the hydrogen generated in theelectrolyzed water. The hydrogen is then collected from the hydrogengenerated in the electrolyzed water, not the gas mixture of hydrogen andoxygen, and is directly mixed with the atomized medicine, where at thistime the gas volume concentration of hydrogen in the inhalation-typepharmaceutical composition will also be larger than 66.66%.

Please refer to FIG. 1. FIG. 1 is a method flowchart illustrating apreparation method for an inhalation-type pharmaceutical composition forthe treatment of Alzheimer's disease according to one embodiment of thepresent invention. As shown in FIG. 1, the preparation method for theinhalation-type pharmaceutical composition of the present inventioncomprises the following steps:

(S1) preparing a first gas, wherein the first gas comprises hydrogen;

(S2) atomizing a medicinal liquid in order to generate an atomizedmedicine, wherein the atomized medicine is selected from a groupcomprising rivastigmine hydrogen tartrate, donepezil hydrochloride,galantamine hydrobromide, memantine hydrochloride, and any combinationthereof; and

(S3) mixing the first gas and the atomized medicine in order to generatethe inhalation-type pharmaceutical composition, wherein the gas volumeconcentration of hydrogen in the inhalation-type pharmaceuticalcomposition is between 2 to 96%.

According to the preparation method for the inhalation-typepharmaceutical composition for the treatment of Alzheimer's diseaseprovided by one embodiment of the present invention, the first gas isgenerated by electrolyzing water in step (S1) of the present invention.The first gas comprises a gas mixture of hydrogen and oxygen, where thevolume ratio of hydrogen to oxygen is 2:1. In the embodiment, the gasvolume concentration of hydrogen in the inhalation-type pharmaceuticalcomposition is between 2 to 66.66%, but is not limited to this range.

Please refer to FIG. 2. FIG. 2 is a method flowchart illustrating apreparation method for an inhalation-type pharmaceutical composition forthe treatment of Alzheimer's disease according to another embodiment ofthe present invention. As shown in FIG. 2, another preparation methodfor the inhalation-type pharmaceutical composition of the presentinvention comprises the following steps:

(S21) preparing a first gas, wherein the first gas comprises hydrogen;

(S22) atomizing a medicinal liquid in order to generate an atomizedmedicine, wherein the atomized medicine is selected from a groupcomprising rivastigmine hydrogen tartrate, donepezil hydrochloride,galantamine hydrobromide, memantine hydrochloride, and any combinationthereof;

(S23) preparing a second gas; and

(S24) mixing the first gas, the second gas, and the atomized medicine inorder to generate the inhalation-type pharmaceutical composition.

According to the preparation method for the inhalation-typepharmaceutical composition for the treatment of Alzheimer's diseaseprovided by one embodiment of the present invention, the first gas isgenerated by electrolyzing water in step (S21) of the present invention.The first gas comprises a gas mixture of hydrogen and oxygen, where thevolume ratio of hydrogen to oxygen is 2:1. Furthermore, the gas volumeconcentration of hydrogen in the inhalation-type pharmaceuticalcomposition can be reduced by adding the second gas. In the presentembodiment, the gas volume concentration of hydrogen in theinhalation-type pharmaceutical composition is between 4.7 to 66.66%, butis not limited to this range.

In another embodiment of the present invention, the required hydrogencan also be provided by using a hydrogen bottle. The hydrogen providedby the hydrogen bottle is then mixed with the atomized medicine, whereat this time the gas volume concentration of hydrogen in theinhalation-type pharmaceutical composition is larger than 66.66%, forexample between 67 to 96%. When a user inhales gas with higher gasvolume concentration of hydrogen, such as the gas volume concentrationof hydrogen being higher than 96%, namely gas inhaled by the user haslower gas volume concentration of oxygen, which would result in lack ofoxygen to the user's body. Therefore, it is imperative that theinvention controls the volume concentration of hydrogen to not be higherthan 96%, for example having the gas volume concentration of hydrogen inthe inhalation-type pharmaceutical composition to be between 67 to 90%.In another embodiment of the present invention, hydrogen can also bedirectly collected from the hydrogen generated in the electrolyzedwater. The hydrogen collected from the hydrogen generated in theelectrolyzed water, not a gas mixture of hydrogen and oxygen, isdirectly mixed with the atomized medicine, where at this time the gasvolume concentration of hydrogen in the inhalation-type pharmaceuticalcomposition will also be larger than 66.66%.

Please refer to FIG. 3. FIG. 3 is a schematic diagram of an electrolysisdevice illustrating step (S1) in the preparation method for aninhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease according to one embodiment of the presentinvention. In the present embodiment, the first gas comprising the gasmixture of hydrogen and oxygen can be generated by electrolyzing water,wherein an electrolysis device 100 comprises an electrolysis tank 102,electrolytic water 104, two electrodes 106A and 106B, and a powersupply.

Firstly, the electrolysis tank 102 is used to accommodate theelectrolytic water 104, wherein the main ingredient of the electrolyticwater 104 is pure water, but is not limited thereof. In practicalapplication, electrolytes such as sodium hydroxide, calcium carbonateand sodium chloride can be added into the electrolyzed water 104 asneeded. Then, the electrolysis tank 102 comprises two electrodes 106Aand 106B, wherein the two electrodes 106A and 106B respectivelyrepresent a cathode electrode and an anode electrode. The two electrodes106A and 106B are coupled to a power supply (not shown) in order toprovide the required power to electrolyze the water. In one embodimentof the present invention, the polarity of the two electrodes 106A and106B are fixed, for example, the electrode 106A is the cathode and theelectrode 106B is the anode. In another embodiment of the presentinvention, the polarity of the two electrodes 106A and 106B can bealternated. For example, at a point in time, the electrode 106A is thecathode and the electrode 106B is the anode, but after a predeterminedtime, the electrode 106A changes into the anode and the electrode 106Bchanges into the cathode.

After the two electrodes 106A and 106B are powered, the water 104 in theelectrolysis tank 102 will begin to be electrolyzed in order to generatehydrogen and oxygen. Hydrogen is generated on the cathode and oxygen isgenerated on the anode, and both hydrogen and oxygen are released to theupper part of the electrolysis tank 102 in order to form a first gas108. The first gas 108 is outputted from a first gas line 110 of theelectrolysis tank 102 to be used, but is not limited thereof. In anotherembodiment of the present invention, hydrogen from the cathode andoxygen from the anode are outputted to the electrolysis tank 102 througha gas pipe and then mixed to form the first gas 108.

Hydrogen and oxygen are generated from electrolyzing the water 104,where the volume ratio of hydrogen to oxygen is 2:1. In one embodimentof the present invention, the invention can further add a second gas 112to the inhalation-type pharmaceutical composition to reduce the gasvolume concentration of hydrogen in the inhalation-type pharmaceuticalcomposition. For example, the gas volume concentration of hydrogen inthe inhalation-type pharmaceutical composition can be controlled to bebetween 4.7 to 66.66%. The second gas is a gas selected from a groupcomprising air, water vapor, inert gas, oxygen or any combinationthereof.

Please refer to FIG. 4. FIG. 4 is a schematic diagram of a gas mixingsystem illustrating step (S2) and (S3) in the preparation method of aninhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease according to one embodiment of the presentinvention. In step (S2) and (S3) of the preparation method, a medicinalliquid 220 can be atomized by a gas mixing system 200, and then theatomized medicinal liquid 220 can be mixed with the first gas 108 inorder to generate an inhalation-type pharmaceutical composition 214.

The gas mixing system 200 comprises an atomized/volatile gas mixing tank210. The atomized/volatile gas mixing tank 210 is coupled to theelectrolysis device 100 by the first gas line 110, as shown in FIG. 3,which is used to accept the first gas 108 to mix an atomized medicine212 in order to generate the inhalation-type pharmaceutical composition214. The atomized/volatile gas generator 210 further comprises anoscillator 216, such as an ultrasonic oscillator. The oscillator 216 isadapted to atomize the medicinal liquid 220 in the atomized/volatile gasgenerator 210 in order to generate the atomized medicine 212. Themedicinal liquid 220 can be a group comprising rivastigmine hydrogentartrate, donepezil hydrochloride, galantamine hydrobromide, memantinehydrochloride, and any combination thereof. The above medicine for thetreatment of Alzheimer's disease is well known to those skilled in theart, and hence will not be described in further detail.

In another embodiment of the present invention, the atomized/volatilegas generator 210 can accommodate between 40 c.c. and 100 c.c ofmedicinal liquid, which can be completely atomized within 60 min usingthe atomized/volatile gas generator 210. Therefore, the gas yield of theatomized medicine can be between about 0.67 cc/min to about 1.67 cc/min,and the gas yield controlled by the electrolysis tank 102 can be betweenabout 2,000 cc/min to about 3,000 cc/min, wherein the gas generated fromthe electrolysis tank only has the gas mixture of hydrogen and oxygen(the volume ratio of hydrogen to oxygen is about 2:1), and thus the gasvolume concentration of hydrogen in the inhalation-type pharmaceuticalcomposition is between 66.61 and 66.65%. The heat is generated from theelectrolysis tank when the electrolytic tank is conducted toelectrolyze. The water in the electrolysis tank will then be evaporatedby the heat generated from the electrolysis tank. Then the gas generatedfrom the electrolysis tank not only has the gas mixture of hydrogen andoxygen but also has a small amount of water vapor, therefore the gasvolume concentration of hydrogen in the inhalation-type pharmaceuticalcomposition will be lower than 66.61%, for example the gas volumeconcentration of hydrogen in the inhalation-type pharmaceuticalcomposition can be between 60 and 66.61%. Evidently, the small amount ofwater vapor can be reduced through cooling. Therefore, theinhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease can be made by mixing the gas mixture of hydrogenand oxygen with the atomized medicine. The gas volume concentration ofhydrogen in the inhalation-type pharmaceutical composition is generallybetween 60%˜66.61%.

In another embodiment of the present invention, the composition ratio ofthe first gas and the atomized medicine in the inhalation-typepharmaceutical composition separately are 35.33˜99.99% and 0.01˜64.67%,which are calculated according to the concentration percentage of thegas, but are not limited thereof. In practical application, thecomposition ratio of the first gas and the atomized medicine can beadjusted according to the patient's situation and is also administereddaily through inhalation at least one to three times, where each sessionmay be in the range of 30 to 60 minutes.

In another embodiment of the present invention, the composition ratio ofthe first gas, the atomized medicine and the second gas in theinhalation-type pharmaceutical composition separately are 33˜97%,0.01˜64%, and 2˜66%, which are calculated according to the concentrationpercentage of the gas, but are not limited thereof. In practicalapplication, the composition ratio of the first gas, the atomizedmedicine and the second gas can be adjusted according to the patient'ssituation and is also administered daily through inhalation at least oneto three times, where each session may be in the range of 30 to 60minutes.

According to the above embodiments of the present invention, theinhalation-type pharmaceutical composition of the present inventioncomprises hydrogen and the atomized medicine in order to form theinhalation-type pharmaceutical composition that is to be inhaled by auser (not shown). Studies have found that there is an instable oxygenspecies (O+), also known as free radicals, in the human body. The freeradicals are usually created due to diseases, diet, environment andone's lifestyle, where the free radicals can be excreted in the form ofwater by reacting with the inhaled hydrogen. Using this method, theamount of free radicals in the human body can be reduced, therebyrestoring the body condition from an acidic state to an alkaline state,which can achieve an anti-oxidation, anti-aging and beauty healtheffect, and even eliminating chronic diseases. In addition, according toclinical studies, the atomized medicinal liquid is 1-5 micro meters andis more easily absorbed by the human body than its non-atomizedcounterpart. That is to say, compared with its non-atomized counterpart,the atomized medicine can achieve the same therapeutic effect with amuch lower dosage. Furthermore, the drug's side effects can be reduceddue to the lower dosage of administered atomized medicine. The medicinalliquid may be the liquid mixture that is oral medicine dissolved in thewater. Therefore, the inhalation-type pharmaceutical composition havinghydrogen and the atomized medicine may provide an excellent therapeuticeffect.

Compared to conventional technology, the present invention provides aninhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease and the preparation method thereof. Theinhalation-type pharmaceutical composition of the present invention canprovide the convenience of taking medicine and removing harmful radicalsin the body of the patient through the use of hydrogen while alsoincreases the absorption effect of the medicine for the patient by usingan atomized medicine. At the same time, because the use of the smallamount of the vaporized pharmaceutical liquid can indirectly reduce theside effects on the user.

With the examples and explanations mentioned above, the features andspirits of the invention are hopefully well described. More importantly,the present invention is not limited to the embodiment described herein.Those skilled in the art will readily observe that numerousmodifications and alterations of the device may be made while retainingthe teachings of the invention. Accordingly, the above disclosure shouldbe construed as limited only by the meets and bounds of the appendedclaims.

The invention claimed is:
 1. An inhalation-type pharmaceuticalcomposition for the treatment of Alzheimer's disease, comprising a firstgas and an atomized medicine, wherein the first gas comprises hydrogen,the gas volume concentration of hydrogen in the inhalation-typepharmaceutical composition is between 4.7 to 66.66%, the atomizedmedicine is selected from a group comprising rivastigmine hydrogentartrate, donepezil hydrochloride, galantamine hydrobromide, memantinehydrochloride, and any combination thereof.
 2. The inhalation-typepharmaceutical composition for the treatment of Alzheimer's disease ofclaim 1, wherein the first gas further comprises oxygen.
 3. Theinhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease of claim 2, wherein the first gas is a gas mixtureof hydrogen and oxygen generated from electrolyzing water, where thevolume ratio of hydrogen to oxygen is 2:1.
 4. The inhalation-typepharmaceutical composition for the treatment of Alzheimer's disease ofclaim 2, further comprising a second gas for reducing the gas volumeconcentration of hydrogen in the inhalation-type pharmaceuticalcomposition, wherein the second gas is a gas selected from a groupcomprising air, water vapor, inert gas, oxygen or any combinationthereof.
 5. The inhalation-type pharmaceutical composition for thetreatment of Alzheimer's disease of claim 1, wherein the gas volumeconcentration of hydrogen in the inhalation-type pharmaceuticalcomposition is between 60 to 66.66%.
 6. The inhalation-typepharmaceutical composition for the treatment of Alzheimer's disease ofclaim 1, wherein the atomized medicine is generated by atomizing orvaporizing a medicinal liquid.
 7. The inhalation-type pharmaceuticalcomposition for the treatment of Alzheimer's disease of claim 6, whereinthe medicinal liquid is selected from a group comprising rivastigminehydrogen tartrate, donepezil hydrochloride, galantamine hydrobromide,memantine hydrochloride, and any combination thereof.
 8. A preparationmethod for an inhalation-type pharmaceutical composition for thetreatment of Alzheimer's disease, comprising the following steps: (S1)preparing a first gas, wherein the first gas comprising hydrogen; (S2)atomizing a medicinal liquid in order to generate an atomized medicine,where the atomized medicine is selected from a group comprisingrivastigmine hydrogen tartrate, donepezil hydrochloride, galantaminehydrobromide, memantine hydrochloride, and any combination thereof;(S23) preparing a second gas selected from a group comprising air, watervapor, inert gas, oxygen or any combination thereof; and (S3) mixing thefirst gas, the second gas and the atomized medicine in order to generatethe inhalation-type pharmaceutical composition, wherein the gas volumeconcentration of hydrogen in the inhalation-type pharmaceuticalcomposition is between 2 to 96%.
 9. The preparation method for theinhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease of claim 8, wherein the second gas is used forreducing the gas volume concentration of hydrogen in the inhalation-typepharmaceutical composition.
 10. The preparation method for theinhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease of claim 8, wherein in step (S1), the first gas isgenerated by electrolyzing water, the first gas comprises a gas mixtureof hydrogen and oxygen, where the volume ratio of hydrogen to oxygen is2:1.
 11. The preparation method for the inhalation-type pharmaceuticalcomposition for the treatment of Alzheimer's disease of claim 8, whereinthe gas volume concentration of hydrogen in the inhalation-typepharmaceutical composition is between 2 to 66.66%.
 12. The preparationmethod for the inhalation-type pharmaceutical composition for thetreatment of Alzheimer's disease of claim 8, wherein the gas volumeconcentration of hydrogen in the inhalation-type pharmaceuticalcomposition is between 4.7 to 66.66%.
 13. The preparation method for theinhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease of claim 8, wherein the gas volume concentration ofhydrogen in the inhalation-type pharmaceutical composition is between 60to 66.66%.
 14. The preparation method for the inhalation-typepharmaceutical composition for the treatment of Alzheimer's disease ofclaim 8, wherein the gas volume concentration of hydrogen in theinhalation-type pharmaceutical composition is larger than 66.66%.
 15. Aninhalation-type pharmaceutical composition for the treatment ofAlzheimer's disease, comprising a first gas and an atomized medicine,wherein the first gas comprises hydrogen, the gas volume concentrationof hydrogen in the inhalation-type pharmaceutical composition is largerthan 66.66%, the atomized medicine is selected from a group comprisingrivastigmine hydrogen tartrate, donepezil hydrochloride, galantaminehydrobromide, memantine hydrochloride, and any combination thereof.